HYBRITECH PURSUING DEVELOPMENT OF CANCER SUSCEPTIBILITY TESTS
This article was originally published in The Gray Sheet
Executive Summary
HYBRITECH PURSUING DEVELOPMENT OF CANCER SUSCEPTIBILITY TESTS based on the BRCA1 tumor suppressor gene that demonstrates susceptibility to breast and ovarian cancer. Discovery of the gene was announced at a Sept. 14 National Institutes of Health press briefing in Bethesda, Maryland.